Systematic review of the biology and medical management of respiratory syncytial virus infection

Respiratory Care

Volumn 48, Issue 3, 2003, Pages 209-231

  Black, Craig Patrick ^a,b  

^a UNIVERSITY OF TOLEDO   (United States)

^b ST VINCENT MERCY MEDICAL CENTER   (United States)

Author keywords

Pediatric; Respiratory syncytial virus; RSV

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DORNASE ALFA; IPRATROPIUM BROMIDE; NITRIC OXIDE; ORCIPRENALINE; OXYGEN; PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; SALBUTAMOL;

AIRWAY OBSTRUCTION; ARTIFICIAL VENTILATION; ATELECTASIS; BIOLOGY; CELLULAR IMMUNITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; ECONOMIC ASPECT; EPITHELIUM CELL; EVIDENCE BASED PRACTICE; EXTRACORPOREAL OXYGENATION; FOMITE; GAS EXCHANGE; HEALTH CARE COST; HELIUM OXYGEN BREATHING; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMORAL IMMUNITY; HYPERINFLATION; IMMUNE RESPONSE; IMMUNITY; INFECTION CONTROL; LABORATORY DIAGNOSIS; MORBIDITY; MORTALITY; NONHUMAN; OUTPATIENT; OUTPATIENT CARE; OXYGEN THERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; RISK FACTOR; SECRETIONS; SUCTION; SYSTEMATIC REVIEW; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS TRANSMISSION; WHEEZING; DISEASE MANAGEMENT; INFANT; NEWBORN; REVIEW; UNITED STATES; VIRUS INFECTION;

DISEASE MANAGEMENT; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY THERAPY; RISK FACTORS; UNITED STATES;

EID: 0038681890     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (214)

1. Dennehy PH. Epidemiology and risk factors. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:37-71.
2. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001:183(1):16-22.
3. MacDonald NE, Hall CB, Suffin SC, Alexson D, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307(7):397-400.
4. McBride JT. Pulmonary function changes in children after respiratory syncytial virus infection in infancy. J Pediatr 1999;135(2 Pt 2):28-32.
5. Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med 1997;102(3A):61-70; discussion 75-76.
6. Hemming VG. Respiratory syncytial virus: a brief history. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:7-23.
7. Adams J. Primary virus pneumonitis with cytoplasmic inclusion bodies: a study of an epidemic involving thirty-two infants with nine deaths. JAMA 1941;116:925-933.
8. Hilleman MR. Respiratory syncytial virus. Am Rev Respir Dis 1963;88:181-197.
9. Jeffcoate TN. Vaccine against respiratory syncytial virus. Lancet 1969;2(7615):311.
10. Rodriguez WJ, Kim HW, Brandt CD, Fink RJ, Getson PR, Arrobio J, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J 1987;6(2):159-163.
11. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection: a randomized double-blind study. N Engl J Med 1983;308(24):1443-1447.
12. Smith DW, Frankel LR, Mathers LH, Tang ATS, Arriagno RL, Porber CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus. N Engl J Med 1991;325(1):24-29.
13. American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996;97(1):137-140.
14. Bowden RA. Respiratory virus infection after marrow transplant: The Fred Hutchinson Cancer Research Center experience. Am J Med 1997;102(3A):27-30; discussion 42-43.
15. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997;99(1):93-99.
16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact RSV Study Group. Pediatrics 1998;102(3):531-537.
17. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial- virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979;300(10):530-534.
18. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973;288(10):498-505.
19. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140(6):543-546.
20. Monto AS, Lim SK. The Tecumseh study of respiratory illness. III. Incidence and periodicity of respiratory syncytial virus and Mycoplasma pneumoniae infections. Am J Epidemiol 1971;94(3):290-301.
21. Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990;161(3):402-406.
22. Welliver R, Cherry JD. Bronchiolitis and infectious asthma. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases, 2nd ed. Philadelphia: WB Saunders; 1987:278-288.
23. Murphy TF, Henderson FW, Clyde WA Jr, Collier AM, Denny FW. Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol 1981;113(1):12-21.
24. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999:282(15):1440-1446.
25. Carlsen KH, Larsen S, Bjerve O, Leegaard J. Acute bronchiolitis: predisposing factors and characterizations of infants at risk. Pediatr Pulmonol 1987;3(3):153-160.
26. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98(5):708-715.
27. McConnochie KM, Roghmann KJ. Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis. Am J Dis Child 1986;140(8):806-812.
28. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19(7):592-597.
29. Simoes EAF, King SJ, Lehr MV, Groothuis JR. Preterm twins and triplets: a high-risk group for severe respiratory syncytial virus infection. Am J Dis Child 1993;147(3):303-306.
30. Simoes EAF, Groothuis JR. Respiratory syncytial virus prophylaxis - the story so far. Respir Med 2002;96 Suppl B:S15-S24.
31. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88(3):527-532.
32. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113(5):826-830.
33. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, Phelan PD. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998;26(6):371-379.
34. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103(3):619-626.
35. Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV data base. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1999;18(10):866-869.
36. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307(7):397-400.
37. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121(3):348-354.
38. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20(10):1406- 1413.
39. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315(2):77-81.
40. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973;98(4):289-300.
41. Glezen WP. Pathogenesis of bronchiolitis - epidemiologic considerations. Pediatr Res 1977;11(3 Pt 2):239-243.
42. Denny FW, Collier AM, Henderson FW, Clyde WA Jr. The epidemiology of bronchiolitis. Pediatr Res 1977;11(3 Pt 2):234-236.
43. Brandt CD, Kim HW, Arrobio JO, Jeffries BC, Wood SC, Chanock RM, Parrott RH. Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 1973;98(5):355-364.
44. Vardas E, Blaauw D, McAnerney J. The epidemiology of respiratory syncytial virus (RSV) infections in South African children. S Afr Med J 1999;89(10):1079-1084.
45. Harlap S, Davies AM. Infant admissions to hospital and maternal smoking. Lancet 1974;1(7857):529-532.
46. Hall CB. The nosocomial spread of respiratory syncytial virus infections. Annu Rev Med 1983;34:311-319.
47. Langley JM, LeBlanc JC, Wang EE, Law BJ, MacDonald NE, Mitchell I, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada study. Pediatrics 1997;100(6):943-946.
48. Hall CB. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Infect Dis 2000;31(2):590-596.
49. Hall CB, Geiman J, Douglas RG Jr, Meagher MP. Control of nosocomial respiratory syncytial viral infections. Pediatrics 1978;62(5):728-732.
50. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163(4):693-698.
51. Hall CB. Respiratory syncytial virus and parainfluenza virus. New Engl J Med 2001;344(25):1917-1928.
52. Cane PA. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2001;11(2):103-116.
53. Alberts B, Bray D, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Essential cell biology: an introduction to the molecular biology of the cell. New York: Garland Publishing; 1998:297-300.
54. Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, Anderson LJ. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990;162(6):1283-1290.
55. Freymuth F, Petitjean J, Pothier P, Brouard J, Norrby E. Prevalence of respiratory syncytial virus subgroups A and B in France from 1982 to 1990. J Clin Microbiol 1991:29(3):653-655.
56. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis 1997;175(4):814-820.
57. Wilson SD, Roberts K, Hammond K, Ayres JG, Cane PA. Estimation of incidence of respiratory syncytial virus infection in school-children using salivary antibodies. J Med Virol 2000;61(1):81-84.
58. Chartrand SA. Current prevention strategies. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000: 153-175.
59. van Schaik SM, Welliver RC, Kimpen JLL. Novel pathways in the pathogenesis of respiratory syncytial virus disease. Pediatr Pulmonol 2000;30(2):131-138.
60. Dargaville PA, South M, McDougall PN. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child 1996;75(2):133-136.
61. van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC II, Welliver RC. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999;103(4):630-636.
62. Welliver RC. Immune response. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:94-121.
63. Kimpen JLL, Rich GA, Hohar CK, Ogra PL. Mucosal T cell distribution during infection with respiratory syncytial virus. J Med Virol 1992;36(3):172-179.
64. Hall CB, Douglas RG Jr, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980;141(1):98-102.
65. Hall CB, Douglas RG Jr. Modes of transmission of respiratory syncytial virus. J Pediatr 1981;99(1):100-103.
66. Hall CB. Pathology and pathogenicity. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:72-93.
67. American Academy of Pediatrics Committee on Infectious Diseases. In: Peter G, editor. 1997 Red Book: Report of the Committee on Infectious Diseases, 24th edition. Elk Grove Village, Illinois: American Academy of Pediatrics;1997:443-447.
68. Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr 1976;89(1):11-15.
69. Simoes EA, Groothuis JR, Tristram DA, Allessi K, Lehr MV, Siber GR, Welliver RC. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children. J Pediatr 1996;129(2):214-219.
70. Ng YT, Cox C, Atkins J, Butler IJ. Encephalopathy associated with respiratory syncytial virus bronchiolitis. J Child Neurol 2001;16(2):105-108.
71. MacDonald NE, Wolfish N, McLaine P, Phipps P, Rossier E. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr 1986;108(3):378-382.
72. Bachmann DC, Pfenninger J. Respiratory syncytial virus triggered adult respiratory distress syndrome in infants: a report of two cases. Intensive Care Med 1994;20(1):61-63.
73. Simoes EAF. Treatment and prevention of respiratory syncytial virus lower respiratory tract infection: long-term effects on respiratory outcomes. Am J Respir Crit Care Med 2001;163(3 Pt 2):S14-S17.
74. Oddy WH, de Klerk NH, Sly PD, Holt PG. The effects of respiratory infections, atopy, and breastfeeding on childhood asthma. Eur Respir J 2002;19(5):899-905.
75. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161(5):1501-1507.
76. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354(9178):541-545.
77. Pullan CR, Hey EN. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. Br Med J (Clin Res Ed) 1982;284(6330):1665-1669.
78. Kimpen JLL, Simoes EAF. Respiratory syncytial virus and reactive airway disease: new developments prompt a new review. Am J Respir Crit Care Med 2001;163(3 Pt 2):S1.
79. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med 2001;163(3 Pt 2):S2-S6.
80. Kneyber MCJ, Steyerberg EW, de Groot R, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr 2000;89(6):654-660.
81. Wennergren G, Kristjansson S. Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Respir J 2001;18(6):1044-1058.
82. Adkins B, Bu Y, Geuvara. The generation of Th memory in neonates versus adults: prolonged primary Th2 effector function and impaired development of Th1 memory effector function in murine neonates. J Immunol 2001;166(2):918-925.
83. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002;196(10):1381-1386.
84. Welliver RC. Immunologic mechanisms of virus-induced wheezing and asthma. J Pediatr 1999;135(2 Pt 2):14-20.
85. Holt PG, Sly PD. Interactions between RSV infection, asthma, and atopy: unraveling the complexities. J Exp Med 2002;196(10):1271-1275.
86. Holt PG, Sly PD. Interactions between respiratory tract infections and atopy in the aetiology of asthma. Eur Respir J 2002;19(3):538-545.
87. Everard ML. Acute bronchiolitis and pneumonia in infancy resulting from the respiratory syncytial virus. In: Taussig LM, Landau LI, editors. Pediatric respiratory medicine. St Louis: Mosby; 1999:580-595.
88. Bauman LA, Hansell DR. Pediatric airway disorders and parenchymal lung diseases. In: Czervinske MP, Barnhart SL, editors. Perinatal and pediatric respiratory care. Philadelphia: Saunders; 2003:549-574.
89. Noyola DE, Demmler GJ. Laboratory diagnosis. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:122-135.
90. Rakshi K, Couriel JM. Management of acute bronchiolitis. Arch Dis Child 1994;71(5):463-469.
91. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practices of infectious diseases, 4th ed. New York: Churchill Livingstone; 1995:1501-1508.
92. Kornecki A, Shemie SD. Bronchodilators and RSV-induced respiratory failure: agonizing about β2 agonists (editorial). Pediatr Pulmonol 1998;26(1):4-5.
93. Rutter N, Milner AD, Hiller EJ. Effect of bronchodilators on respiratory resistance in infants and young children with bronchiolitis and wheezy bronchitis. Arch Dis Child 1975;50(9):719-722.
94. Stokes GM, Milner AD, Hodges IG, Henry RL, Elphick MC. Nebulised therapy in acute severe bronchiolitis in infancy. Arch Dis Child 1983;58(4):279-282.
95. Soto ME, Sly PD, Uren E, Taussig LM, Landau LI. Bronchodilator response during acute viral bronchiolitis in infancy. Pediatr Pulmonol 1985;1(2):85-90.
96. O'Callaghan C, Milner AD, Swarbrick A. Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants. Lancet 1986;2(8521-8522):1424-1425.
97. Prendiville A, Green S, Silverman M. Paradoxical response to nebulized salbutamol in wheezy infants, assessed by partial expiratory flow-volume curves. Thorax 1987;42(2):86-91.
98. Hughes DM, Lesouef PN, Landau LI. Effect of salbutamol on respiratory mechanics in bronchiolitis. Pediatr Res 1987;22(1):83-86.
99. Mallory GB Jr, Motoyama EK, Koumbourlis AC, Mutich RL, Nakayama DK. Bronchial reactivity in infants in acute respiratory failure with viral bronchiolitis. Pediatr Pulmonol 1989;6(4):253-259.
100. Schuh S, Canny G, Reisman JJ, Kerem E, Bentur L, Petric M, Levison H. Nebulized albuterol in acute bronchiolitis. J Pediatr 1990;117(4):633-637.
101. Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM. Randomized trial of salbutamol in acute bronchiolitis. J Pediatr 1991;118(5):807-811.
102. Seidenberg J, Mir Y, von der Hardt H. Hypoxaemia after nebulised salbutamol in wheezy infants: the importance of aerosol acidity. Arch Dis Child 1991;66(6):672-675.
103. Ho L, Collis G, Landau LI, Le Souef PN. Effect of salbutamol on oxygen saturation in bronchiolitis. Arch Dis Child 1991;66(9):1061-1064.
104. Sly PD, Lanteri CJ, Raven JM. Do wheezy infants recovering from bronchiolitis respond to inhaled salbutamol? Pediatr Pulmonol 1991;10(1):36-39.
105. Wang EE, Milner R, Allen U, Maj H. Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. Arch Dis Child 1992;67(3):289-293.
106. Alario AJ, Lewander WJ, Dennehy P, Seifer R, Mansell AL. The efficacy of nebulized metaproterenol in wheezing infants and young children. Am J Dis Child 1992;146(4):412-418.
107. Tepper RS, Rosenberg D, Eigen H, Reister T. Bronchodilator responsiveness in infants with bronchiolitis. Pediatr Pulmonol 1994;17(2):81-85.
108. Hammer J, Numa A, Newth CJL. Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr 1995;127(3):485-490.
109. Torres A Jr, Anders M, Anderson P, Heulitt MJ. Efficacy of metered-dose inhaler administration of albuterol in intubated infants. Chest 1997;112(2):484-490.
110. Derish M, Hodge G, Dunn C, Ariagno R. Aerosolized albuterol improves airway reactivity in infants with acute respiratory failure from respiratory syncytial virus. Pediatr Pulmonol 1998;26(1):12-20.
111. Modl M, Eber E, Weinhandl E, Gruber W, Zach MS. Assessment of bronchodilator responsiveness in infants with bronchiolitis: a comparison of the tidal and the raised volume rapid thoracoabdominal compression technique. Am J Respir Crit Care Med 2000;161(3 Pt 1);763-768.
112. Totapally BR, Demerci C, Zureikat G, Nolan B. Tidal breathing flow-volume loops in bronchiolitis in infancy: the effect of albuterol. Crit Care 2002;6(2):160-165.
113. Gadomski AM, Lichenstein R, Horton L, King J, Keane V, Permutt T. Efficacy of albuterol in the management of bronchiolitis. Pediatrics 1994;93(6 Pt 1):907-912.
114. Henry RL, Milner AD, Stokes GM. Ineffectiveness of ipratropium bromide in acute bronchiolitis. Arch Dis Child 1983;58(11):925-926.
115. Schuh S, Johnson D, Canny G, Reisman J, Shields M, Kovesi T, et al. Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis. Pediatrics 1992;90(6):920-923.
116. Dobson JV, Stephens-Groff SM, McMahon SR, Stemmler MM, Brallier SL, Bay C. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics 1998;101(3 Pt 1):361-368.
117. Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis. Arch Pediatr Adolesc Med 1996;150(11):1166-1172.
118. Flores G, Horwitz RI. Efficacy of β2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics 1997;100(2 Pt 1):233-239.
119. Kellner JD, Ohlsson A, Gadomski AM, Wang EEL. Bronchodilators for bronchiolitis (Cochrane Review). In: The Cochrane Library, Issue 4 2002. Oxford: Update Software. Available at http://www.update-software.com/abstracts/ titlelist.htm. Accessed Jan 16, 2003
120. Schindler M. Do bronchodilators have an effect on bronchiolitis? Crit Care 2002;6(2):111-112.
121. Amirav I, Balanov I, Gorenberg M, Luder AS, Newhouse MT, Groshar D. β-agonist aerosol distribution in respiratory syncytial virus bronchiolitis in infants. J Nucl Med 2002;43(4):487-491.
122. Lowell DI, Lister G, Von Koss H, McCarthy P. Wheezing in infants: the response to epinephrine. Pediatrics 1987;79(6):939-945.
123. Wennergren G, Kristjansson S, Sten G, Bjure J, Engstrom I. Nebulized racemic adrenaline for wheezy bronchitis. Acta Paediatr Scand 1991;80(3):375-377.
124. Kristjansson S, Lodrup Carlsen KC, Wennergren G, Strannegard IL, Carlsen KH. Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers. Arch Dis Child 1993;69(6):650-654.
125. Reijonen T, Korppi M, Pitkakangas S, Tenhola S, Remes K. The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis. Arch Pediatr Adolesc Med 1995;149(6):686-692.
126. Menon K, Sutcliffe R, Klassen TP. A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis. J Pediatr 1995;126(6):1004-1007.
127. Henderson AJ, Arnott J, Young S, Warshawski T, Landau LI, LeSouef PN. The effect of inhaled adrenaline on lung function of recurrently wheezy infants less than 18 months old. Pediatr Pulmonol 1995;20(1):9-15.
128. Lodrup Carlsen KC, Carlsen KH. Inhaled nebulized adrenaline improves lung function in infants with acute bronchiolitis. Respir Med 2000;94(7):709-714.
129. Bertrand P, Aranibar H, Castro E, Sanchez I. Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis. Pediatr Pulmonol 2001;31(4):284-288.
130. Numa AH, Williams GD, Dakin CJ. The effect of nebulized epinephrine on respiratory mechanics and gas exchange in bronchiolitis. Am J Respir Crit Care Med 2001;164(1):86-91.
131. Abul-Ainine A, Luyt D. Short term effects of adrenaline in bronchiolitis: a randomised controlled trial. Arch Dis Child 2002;86(4):276-279.
132. Barr FE, Patel NR, Newth CJ. The pharmacologic mechanism by which inhaled epinephrine reduces airway obstruction in respiratory syncytial virus-associated bronchiolitis. J Pediatr 2000;136(5):699-700.
133. Nasr SZ, Strouse PJ, Soskolne E, Maxvold NJ, Garver KA, Rubin BK, Moler FW. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001;120(1):203-208.
134. Merkus PJ, de Hoog M, van Gent R, de Jongste JC. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001;18(4):734-737.
135. Dabbous IA, Tkachyk JS, Stamm SJ. A double blind study of the effects of corticosteroids in the treatment of bronchiolitis. Pediatrics 1966;37(3):477-484.
136. Springer C, Bar-Yishay E, Uwayyed K, Avital A, Vilozni D, Godfrey S. Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis. Pediatr Pulmonol 1990;9(3):181-185.
137. Reijonen T, Korppi M, Kuikka L, Remes K. Anti-inflammatory therapy reduces wheezing after bronchiolitis. Arch Pediatr Adolesc Med 1996;150(5):512-517.
138. Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listernick R. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 1996;348(9023):292-295.
139. Klassen TP, Sutcliffe T, Watters LK, Wells GA, Allen UD, Li M. Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial. J Pediatr 1997;130(2):191-196.
140. van Woensel JB, Wolfs TF, van Aalderen WM, Brand PL, Kimpen JL. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. Thorax 1997;52(7):634-637.
141. De Boeck K, Van der Aa N, Van Lierde S, Corbeel L, Eeckels R. Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study. J Pediatr 1997;131(6):919-921.
142. Richter H, Seddon P. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. J Pediatr 1998;132(5):849-853.
143. Berger I, Argaman Z, Schwartz SB, Segal E, Kiderman A, Branski D, Kerem E. Efficacy of corticosteroids in acute bronchiolitis: short-term and long-term follow-up. Pediatr Pulmonol 1998;26(3):162-166.
144. Bulow SM, Nir M, Levin E, Friis B, Thomsen LL, Nielsen JE, et al. Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Pediatrics 1999;104(6):e77.
145. Wong JY, Moon S, Beardsmore C, O'Callaghan C, Simpson H. No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis. Eur Respir J 2000;15(2):388-394.
146. Cade A, Brownlee KG, Conway SP, Haigh D, Short A, Brown J, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child 2000;82(2):126-130.
147. Goebel J, Estrada B, Quinonez J, Nagji N, Sanford D, Boerth RC. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. Clin Pediatr (Phila) 2000;39(3):213-219.
148. Kajosaari M, Syvanen P, Forars M, Juntunen-Backman K. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma. Pediatr Allergy Immunol 2000;11(3):198-202.
149. van Woensel JBM, Kimpen JLL, Sprikkelman AB, Ouwehand A, van Aalderen WMC. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus. Pediatr Pulmonol 2000;30(2):92-96.
150. Schuh S, Coates AL, Binnie R, Allin T, Goia C, Corey M, Dick PT. Efficacy of oral dexamethasone in outpatients with acute bronchiolitis. J Pediatr 2002;140(1):27-32.
151. Fox GF, Everard ML, Marsh MJ, Milner AD. Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing. Arch Dis Child 1999;80(4):343-347.
152. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics 2000;105(4):E44.
153. Rodriguez WJ. Therapy of RSV. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:136-152.
154. Randolph AG, Wang EEL. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract (Cochrane Review). In: The Cochrane Library, Issue 4 2002. Oxford: Update Software. Available at http://www.update-software.com/abstracts/titlelist.htm. Accessed Jan 16, 2003
155. Taber LH, Knight V, Gilbert BE, McClung HW, Wilson SZ, Norton HJ, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983;72(5):613-618.
156. Barry W, Cockburn F, Cornall R, Price JF, Sutherland G, Vardag A. Ribavirin aerosol for acute bronchiolitis. Arch Dis Child 1986;61(6):593-597.
157. Conrad DA, Christenson JC, Waner JL, Marks MI. Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. Pediatr Infect Dis J 1987;6(2):152-158.
158. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985;254(21):3047-3051.
159. Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 1990;117(5):792-798.
160. Hall CB. Ribavirin: beginning the blitz on respiratory viruses? Pediatr Infect Dis 1985;4(6):668-671.
161. McBride JT. Study design considerations for ribavirin: efficacy studies. Pediatr Infect Dis J 1990;9(9 Suppl)S74-S78:
162. Meert KL, Sarnaik AP, Gelmini MJU, Lieh-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 1994;22(4):566-572.
163. Guerguerian AM, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis: a randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160(3):829-834.
164. Moler FW, Steinhart CM, Ohmit SE, Stidham GL. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group. J Pediatr 1996;128(3):422-428.
165. Law BJ, Wang EE, MacDonald N, McDonald J, Dobson S, Boucher F, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV database. Pediatrics 1997;99(3):E7.
166. Ohmit SE, Moler FW, Monto AS, Khan AS. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. J Clin Epidemiol 1996;49(9):963-967.
167. Krilov LR, Mandel FS, Barone SR, Fagin JC. Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987; potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group. Pediatr Infect Dis J 1997;16(3):273-276.
168. Long CE, Voter KZ, Barker WH, Hall CB. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr Infect Dis J 1997;16(11):1023-1028.
169. Edell D, Bruce E, Hale K, Edell D, Khoshoo V. Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report. Pediatr Pulmonol 1998;25(3):154-158.
170. Everard ML, Swarbrick A, Rigby AS, Milner AD. The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity. Respir Med 2001;95(4):275-280.
171. Edell D, Khoshoo V, Ross G, Salter K. Early ribavirin treatment of bronchiolitis: effect on long-term respiratory morbidity. Chest 2002;122(3):935-939.
172. McBride JT, McConnochie KM. RSV, recurrent wheezing, and ribavirin (editorial). Pediatr Pulmonol;1998;25(3):145-146.
173. Ballard J, Salyer J. Use of a bronchiolitis symptom scoring system in infants (abstract). Respir Care 2001;47(10):1118.
174. McKinley G, Ballard J, Salyer J. The effect of NP suctioning on symptom scores in bronchiolitis patients (abstract). Respir Care 2001;47(10):1071.
175. Zemlicka-Dunn T, Ballard J, Salyer J. The association between nasopharyngeal suction and oxygen requirements in bronchiolitis patients (abstract). Respir Care 2001;47(10):1071.
176. Bennion K, Ballard J, Salyer J. The interaction of nasopharyngeal (NP) suction and albuterol in the treatment of bronchiolitis: a two year comparison (abstract). Respir Care 2001;47(10):1072.
177. Weber JE, Chudnofsky CR, Younger JG, Larkin GL, Boczar M, Wilkerson MD, et al. A randomized comparison of helium-oxygen mixture (Heliox) and racemic epinephrine for the treatment of moderate to severe croup. Pediatrics 2001;107(6):E96.
178. Jolliet P, Tassaux D, Thouret JM, Chevrolet JC. Beneficial effects of helium:oxygen versus air:oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease. Crit Care Med 1999;27(11):2422-2429.
179. Hollman G, Shen G, Zeng L, Yngsdal-Krenz R, Perloff W, Zimmerman J, Strauss R. Helium-oxygen improves Clinical Asthma Scores in children with acute bronchiolitis. Crit Care Med 1998;26(10):1731-1736.
180. Gross MF, Spear RM, Peterson BM. Helium-oxygen mixture does not improve gas exchange in mechanically ventilated children with bronchiolitis. Crit Care 2000;4(3):188-192.
181. Martinón-Torres F, Rodríguez-Núñez A, Martinón-Sánchez JM. Heliox therapy in infants with acute bronchiolitis. Pediatrics 2002;109(1):68-73.
182. Leclerc F, Riou Y, Martinot A, Storme L, Hue V, Flurin V, Deschildre A, Sadik A. Inhaled nitric oxide for a severe respiratory syncytial virus infection in an infant with bronchopulmonary dysplasia. Intensive Care Med 1994;20(7):511-512.
183. Hoehn T, Krause M, Krueger M, Hentschel R. Treatment of respiratory failure with inhaled nitric oxide and high-frequency ventilation in an infant with respiratory syncytial virus pneumonia and bronchopulmonary dysplasia. Respiration 1998;65(6):477-480.
184. Patel NR, Hammer J, Nichani S, Numa A, Newth CJ. Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. Intensive Care Med 1999;25(1):81-87.
185. Moler FW, Palmisano JM, Green TP, Custer JR. Predictors of outcome of severe respiratory syncytial virus-associated respiratory failure treated with extracorporeal membrane oxygenation. J Pediatr 1993;123(1):46-52.
186. Steinhorn RH, Green TP. Use of extracorporeal membrane oxygenation in the treatment of respiratory syncytial virus bronchiolitis: the national experience, 1983-1988. J Pediatr 1990:116(3):338-342.
187. Khan JY, Kerr SJ, Tometzki A, Tyszezuk L, West J, Sosnowski A, et al. Role of ECMO in the treatment of respiratory syncytial virus bronchiolitis: a collaborative report. Arch Dis Child Fetal Neonatal Ed 1995;73(2):F91-F94.
188. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991;133(11):1135-1151.
189. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102(5):1211-1216.
190. Bomar R, Scott P, Graham L, Divgi V, Lesnick B, Montgomery G, et al. Safe and effective use of Synagis for RSV prophylaxis in 100 high risk children for two consecutive seasons (abstract). Annual Meeting of the Pediatric Academic Societies. 2002;Course 5205, Board 361.
191. Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 2002;96 Suppl B:S31-S35.
192. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176(5):1215-1224.
193. Marchetti A, Simoes EA. The economics of RSV infection, prevention, and treatment. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:201-241.
194. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104(3 Pt 1):419-427.
195. Vogel AM, Lennon DR, Broadbent R, Byrnes CA, Grimwood K, Mildenhall L, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Paediatr Child Health 2002;38(6):550-554.
196. Hall CB, Douglas RG Jr. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used? Am J Dis Child 1981;135(6):512-515.
197. Crowe JE Jr, Englund JA. Future prevention strategies. In: Weisman LE, Groothuis JR, editors. Contemporary diagnosis and management of respiratory syncytial virus. Newtown PA: Handbooks in Health Care Co; 2000:176-200.
198. Englund JA. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. Pediatr Infect Dis J 1994;13(5):449-453.
199. Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995;13(9):847-855.
200. Englund J, Glezen WP, Piedra PA. Maternal immunization against viral disease. Vaccine 1998;16(14-15):1456-1463.
201. Brooks LJ, Cropp GJ. Theophylline therapy in bronchiolitis: a retrospective study. Am J Dis Child 1981;135(10):934-936.
202. Shaw KN, Bell LM, Sherman NH. Outpatient assessment of infants with bronchiolitis. Am J Dis Child 1991;145(2):151-155.
203. Mallory MD, Shay DK, Garrett J, Bordley WC. Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. Pediatrics 2003;111(1):E45-E51.
204. van Steensel-Moll HA, Hazelzet JA, van der Voort E, Neijens H, Hackeng WH. Excessive secretion of antidiuretic hormone in infections with respiratory syncytial virus. Arch Dis Child 1990;65(11):1237-1239.
205. Khoshoo V, Edell D. Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis. Pediatrics 1999;104(6):1389-1390.
206. Hernandez E, Khoshoo V, Thoppil D, Edell D, Ross G. Aspiration: a factor in rapidly deteriorating bronchiolitis in previously healthy infants? Pediatr Pulmonol 2002;33(1):30-31.
207. Antonow JA, Hansen K, McKinstry CA, Byington CL. Sepsis evaluations in hospitalized infants with bronchiolitis. Pediatr Infect Dis J 1998;17(3):231-236.
208. Adcock PM, Sanders CL, Marshall GS. Standardizing the care of bronchiolitis. Arch Pediatr Adolesc Med 1998;152(8):739-744.
209. Perlstein PH, Kotagal UR, Bolling C, Steele R, Schoettker PJ, Atherton HD, Farrell MK. Evaluation of an evidence-based guideline for bronchiolitis. Pediatrics 1999;104(6):1334-1341.
210. Harrison AM, Boeing NM, Domachowske JB, Piedmonte MR, Kanter RK. Effect of RSV bronchiolitis practice guidelines on resource utilization. Clin Pediatr (Phila) 2001;40(9):489-495.
211. Wilson SD, Dahl BB, Wells RD. An evidence-based clinical pathway for bronchiolitis safely reduces antibiotic overuse. Am J Med Qual 2002;17(5):195-199.
212. Todd J, Bertoch D, Dolan S. Use of a large national database for comparative evaluation of the effect of a bronchiolitis/viral pneumonia clinical care guideline on patient outcome and resource utilization. Arch Pediatr Adolesc Med 2002;156(11):1086-1090.
213. Kotagal UR, Robbins JM, Kini NM, Schoettker PJ, Atherton HD, Kirschbaum MS. Impact of a bronchiolitis guideline: a multisite demonstration project. Chest 2002;121(6):1789-1797.
214. Perlstein PH, Kotagal UR, Schoettker PJ, Atherton HD, Farrell MK, Gerhardt WE, Alfaro MP. Sustaining the implementation of an evidence-based guideline for bronchiolitis. Arch Pediatr Adolesc Med 2000;154(10):1001-1007.